Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:why certain trials have failed whereas others have succeeded,what we have learned about the connection between overall survival and progression-free survival as endpoints, andhow the systemic therapy of HCC has evolved.FacultyProf. Peter Galle (Moderator)Prof. Bruno Sangro (Faculty)Dr Anna Saborowski (Faculty)Prof. Arndt Vogel (Faculty)Related episodesS2E15 – JHEP Live – The best animal model for HCC — lost in translationSpecial Edition: Highlights of the Liver Cancer Summit 2022Policy Dialogues Episode 3: Liver Cancer: The risk of ignoranceAll EASL Studio Podcasts are available on EASL Campus.